SUMMARY The hypothesis that phenytoin may antagonise the antidiuretic effect of carbamazepine has been examined by comparing the free water clearance response to a standard water load in 36 patients stabilised on different drug regimes. The diuretic response to the water load was significantly greater in patients receiving chronic treatment with carbamazepine and phenytoin in combination than in matched control subjects receiving carbamazepine as a single drug. Acute administration of phenytoin (1,100 mg), however, had no significant influence on carbamazepineinduced antidiuresis. Evidence is presented that reversal of the antidiuretic effect of carbamazepine by chronic phenytoin administration is secondary to a marked reduction of the serum carbamazepine concentration during combined therapy. These results suggest that the risk of developing water intoxication is greater in patients receiving carbamazepine alone than in those receiving phenytoin in combination. Since the antidiuretic effect is correlated with the serum carbamazepine concentration rather than with the prescribed daily dose, monitoring the serum level of the drug is likely to provide the best rational approach to the prevention of excessive water retention.
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Carbamazepine has antidiuretic properties which have been shown to be positively correlated with the concentration of the drug in serum.1 2 Excessive water retention is relatively common at serum concentration values close to the upper limit of the therapeutic range (12 to 42 Amol/l) and may be troublesome in some patients, particularly those receiving the drug for the treatment of epilepsy and trigeminal neuralgia.'-5 Interestingly, water intoxication appears to be more common in patients treated with carbamazepine alone than in those receiving phenytoin in combination2 and reversal of carbamazepineinduced antidiuresis by phenytoin has been recently described in one patient.6 Although in the latter report the mechanism of the interaction was assumed to be pharmacodynamic, that is, related to the inhibitory action of phenytoin on the release of antidiuretic hormone (ADH) from the posterior pituitary,7 8 
Discussion
This study confirms that carbamazepine treatment may result in an impaired ability to excrete a water load and demonstrates a clear relationship between the magnitude of this effect and the concentration of carbamazepine in serum. A negative correlation between plasma sodium, osmolality and serum carbamazepine concentration has been described before in patients with epilepsy and trigeminal neuralgia.' 2 Our original hypothesis that phenytoin may antagonise the antidiuretic effect of carbamazepine was confirmed by the finding that the diuretic response in patients receiving phenytoin in combination was twice as high as in patients receiving equivalent doses of carbamazepine alone. Our data suggest that the difference could be entirely accounted for by a decrease in serum carbamazepine levels during phenytoin therapy. A lowering effect of phenytoin (and phenobarbitone) on serum carbamazepine levels has been described previously by Christiansen and Dam9 in a comparative study of two different groups of patients, and by Cereghino et al'0 in a within-patient controlled trial. In both of these studies, the magnitude of the effect was remarkably similar to that observed by us. It is of interest that, in our own study, acute administration of phenytoin, 1100 mg over a period of 24 hr, was sufficient to produce a small but significant decrease of the serum carbamazepine concentration in six out of seven subjects. Such 
